March 14 | 2022

2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022

Read more
February 24 | 2022

2cureX publishes interim report for the fourth quarter and all 12 months of 2021

Read more
February 24 | 2022

2cureX offentliggör delårsrapport för det fjärda kvartalen och alla tolv månader 2021

Read more
February 23 | 2022

2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

Read more
February 23 | 2022

2cureX reorganizes to an even stronger distributor focus

Read more
January 21 | 2022

New Institutional shareholder

Read more
January 11 | 2022

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

Read more
January 5 | 2022

IndiTreat® to be distributed in Poland by Perlan Technologies

Read more
December 22 | 2021

First IndiTreat® order received from Labormed, Slovenia

Read more
December 16 | 2021

First hospital joins the IndiTreat® Evaluation Program IGNITE

Read more
December 14 | 2021

2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment

Read more
December 13 | 2021

2cureX reaches the goals for the 2021 rollout plan

Read more
December 9 | 2021

2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey

Read more
November 29 | 2021

EU publishes an article about the successful finalization of 2cureX’s MicroCaT project.

Read more
November 25 | 2021

2cureX offentliggör delårsrapport för det tredje kvartalet och första nio månader 2021

Read more
November 25 | 2021

2cureX publishes interim report for the third quarter and first nine months of 2021

Read more
November 24 | 2021

2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK

Read more
November 23 | 2021

2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021.

Read more